DMAAR
DMAAR
Drugs Made In America Acquisition Corp. RightsIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $143.3K ▼ | $1.97M ▲ | 0% | $0.06 ▲ | $-143.3K ▲ |
| Q4-2025 | $0 | $2.09M ▲ | $212.96K ▼ | 0% | $0.01 ▼ | $-2.09M ▼ |
| Q3-2025 | $0 | $263.7K ▲ | $2.18M ▼ | 0% | $0.07 ▲ | $-263.7K ▼ |
| Q2-2025 | $0 | $131.92K ▼ | $2.29M ▲ | 0% | $0.07 ▼ | $-131.92K ▲ |
| Q1-2025 | $0 | $330.93K | $1.25M | 0% | $130.51 | $-330.93K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $14.89K ▲ | $242.04M ▲ | $7.39M ▲ | $234.64M ▲ |
| Q4-2025 | $6.14K ▲ | $239.92M ▲ | $7.28M ▼ | $232.64M ▲ |
| Q3-2025 | $717 ▼ | $237.63M ▲ | $7.36M ▲ | $230.28M ▲ |
| Q2-2025 | $822 ▼ | $235.21M ▲ | $7.2M ▼ | $228M ▲ |
| Q1-2025 | $923 | $232.81M | $7.25M | $225.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.97M ▲ | $-91.25K ▲ | $0 | $100K ▼ | $8.75K ▲ | $-91.25K ▲ |
| Q4-2025 | $-1.76M ▼ | $-125.18K ▼ | $0 ▼ | $130.6K ▲ | $5.42K ▲ | $-125.18K ▼ |
| Q3-2025 | $785.09K ▼ | $137.91K ▲ | $231.15M ▲ | $-231.3M ▼ | $-105 ▲ | $137.9K ▲ |
| Q2-2025 | $3.69M ▲ | $-300.67K ▼ | $-231.15M | $231.47M ▲ | $-1.27K ▼ | $-300.67K ▼ |
| Q1-2025 | $1.25M | $-251.24K | $-231.15M | $231.4M | $-428 | $-251.24K |
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition Corp. Rights's financial evolution and strategic trajectory over the past five years.
DMAAR currently offers strong liquidity, no financial debt, and a clean capital structure typical of a SPAC, providing a ready pool of capital for the planned transaction. The proposed merger with Power Analytics connects it to a specialized business with proprietary software, patents, and experience in mission-critical power and data environments. If completed, the deal could transform a non-operating shell into a technology-driven enterprise with clear differentiation in digital twins, energy analytics, and quantum-safe cybersecurity.
Key risks stem from both structure and execution. As a SPAC, DMAAR has no operating revenue, negative free cash flow, and negative equity, so its current financials do not represent a going business. The value of the rights depends heavily on the successful closing and terms of the merger with Power Analytics, and on the combined company’s ability to execute in a competitive, fast-evolving technology landscape. Additional uncertainties include potential changes in capital structure at closing, integration challenges, and sensitivity to shifts in regulation and cybersecurity threats.
Looking ahead, DMAAR’s standalone outlook as a shell company is limited; its future is almost entirely defined by the de-SPAC transaction. If the merger closes as planned and Power Analytics can convert its technology advantages into durable customer contracts and steady cash generation, the combined entity could evolve into a meaningful player in the power analytics and cybersecurity space. At the same time, investors should recognize that the historical financials provide little guidance on future operating performance, and that transaction completion, integration, and market execution will largely determine how the story develops from here.
About Drugs Made In America Acquisition Corp. Rights
https://dmaacorp.comDrugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $143.3K ▼ | $1.97M ▲ | 0% | $0.06 ▲ | $-143.3K ▲ |
| Q4-2025 | $0 | $2.09M ▲ | $212.96K ▼ | 0% | $0.01 ▼ | $-2.09M ▼ |
| Q3-2025 | $0 | $263.7K ▲ | $2.18M ▼ | 0% | $0.07 ▲ | $-263.7K ▼ |
| Q2-2025 | $0 | $131.92K ▼ | $2.29M ▲ | 0% | $0.07 ▼ | $-131.92K ▲ |
| Q1-2025 | $0 | $330.93K | $1.25M | 0% | $130.51 | $-330.93K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $14.89K ▲ | $242.04M ▲ | $7.39M ▲ | $234.64M ▲ |
| Q4-2025 | $6.14K ▲ | $239.92M ▲ | $7.28M ▼ | $232.64M ▲ |
| Q3-2025 | $717 ▼ | $237.63M ▲ | $7.36M ▲ | $230.28M ▲ |
| Q2-2025 | $822 ▼ | $235.21M ▲ | $7.2M ▼ | $228M ▲ |
| Q1-2025 | $923 | $232.81M | $7.25M | $225.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.97M ▲ | $-91.25K ▲ | $0 | $100K ▼ | $8.75K ▲ | $-91.25K ▲ |
| Q4-2025 | $-1.76M ▼ | $-125.18K ▼ | $0 ▼ | $130.6K ▲ | $5.42K ▲ | $-125.18K ▼ |
| Q3-2025 | $785.09K ▼ | $137.91K ▲ | $231.15M ▲ | $-231.3M ▼ | $-105 ▲ | $137.9K ▲ |
| Q2-2025 | $3.69M ▲ | $-300.67K ▼ | $-231.15M | $231.47M ▲ | $-1.27K ▼ | $-300.67K ▼ |
| Q1-2025 | $1.25M | $-251.24K | $-231.15M | $231.4M | $-428 | $-251.24K |
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition Corp. Rights's financial evolution and strategic trajectory over the past five years.
DMAAR currently offers strong liquidity, no financial debt, and a clean capital structure typical of a SPAC, providing a ready pool of capital for the planned transaction. The proposed merger with Power Analytics connects it to a specialized business with proprietary software, patents, and experience in mission-critical power and data environments. If completed, the deal could transform a non-operating shell into a technology-driven enterprise with clear differentiation in digital twins, energy analytics, and quantum-safe cybersecurity.
Key risks stem from both structure and execution. As a SPAC, DMAAR has no operating revenue, negative free cash flow, and negative equity, so its current financials do not represent a going business. The value of the rights depends heavily on the successful closing and terms of the merger with Power Analytics, and on the combined company’s ability to execute in a competitive, fast-evolving technology landscape. Additional uncertainties include potential changes in capital structure at closing, integration challenges, and sensitivity to shifts in regulation and cybersecurity threats.
Looking ahead, DMAAR’s standalone outlook as a shell company is limited; its future is almost entirely defined by the de-SPAC transaction. If the merger closes as planned and Power Analytics can convert its technology advantages into durable customer contracts and steady cash generation, the combined entity could evolve into a meaningful player in the power analytics and cybersecurity space. At the same time, investors should recognize that the historical financials provide little guidance on future operating performance, and that transaction completion, integration, and market execution will largely determine how the story develops from here.

CEO
Roger Bendelac
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+

